European Commission Approves J&J's TECVAYLI for Relapsed Multiple Myeloma

The European Commission has approved Johnson & Johnson's TECVAYLI® (teclistamab) as a monotherapy for adults with relapsed and refractory multiple myeloma. This decision expands treatment options for patients who have exhausted prior therapies, including anti-CD38 antibodies and immunomodulatory agents. The approval offers a potential new standard of care for this complex blood cancer, providing hope for those with limited alternatives.